Research Topics
| Michael T MilanoSummaryAffiliation: University of Chicago Country: USA Publications
|
Detail Information
Publications
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcomeMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 59:445-53. 2004..To assess the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) in pancreatic and bile duct (cholangiocarcinoma) malignancies...- Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinomaJoseph K Salama
Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637-1470, USA
Int J Radiat Oncol Biol Phys 64:382-91. 2006..Owing to the substantial toxicity and lack of an optimal regimen, reirradiation of recurrent head-and-neck cancer should be limited to clinical trials... - Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapyMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 61:1096-106. 2005..5-Gy) radiotherapy delivered on alternating weeks (TFGX(2)) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX(2) in a subset of patients previously irradiated to the head and neck... - Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directionsMichael T Milano
Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL 60637, USA
Int J Oncol 28:1141-51. 2006..Building on the present clinical experience, future directions include more directed efforts at reducing toxicity, with better planning software and planning techniques... - Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancerJoseph K Salama
Departments of Radiation and Cellular Oncology, University of Chicago, 5758 S. Maryland Avenue, Chicago, IL 60637-1470, USA
Cancer J 11:140-6. 2005..DISCUSSION: The maximum tolerated dose and recommended phase II dose of CPT-11 with hyperfractionated radiation therapy is 10 mg/m(2)/d... - Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcomeMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA
Int J Radiat Oncol Biol Phys 63:354-61. 2005..Compared with historical controls, local control is not compromised despite efforts to increase conformality and reduce normal structure dose... - Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neckMichael T Milano
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
Clin Cancer Res 10:4922-32. 2004..Refinements in radiotherapy, including intensity-modulated radiation therapy, may improve the tolerance for this regimen... - Reirradiation of recurrent head and neck cancers with curative intentSteven J Chmura
Department of Radiation and Cellular Oncology, 5758 S Maryland, MC 9006, Chicago, IL 60637, USA
Semin Oncol 31:816-21. 2004..Reirradiation with chemotherapy is appropriate for patients with a goal of long-term local control of disease and curative intent, despite the risk of significant acute and late toxicities... - Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicityAshesh B Jani
Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois 60637, USA
Urology 67:147-51. 2006..To provide a single-institution analysis of the influence of pelvic intensity-modulated radiotherapy (RT) on acute genitourinary (GU) and gastrointestinal (GI) toxicity... - Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive reviewJohnny Kao
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL 60637, USA
Cancer Treat Rev 29:21-30. 2003..The results of reirradiation in recurrent head and neck cancer and the prognostic factors predicting outcome in this patient population are reviewed... - Intensity-modulated radiotherapy and the InternetDavid A Schomas
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637, USA
Cancer 101:412-20. 2004..26). CONCLUSIONS: In general, the content and quality of patient-oriented information regarding IMRT on the Internet were poor. Patients and their physicians need to be aware of these problems when selecting treatment courses... - Stereotactic Body Radiation Therapy (SBRT) for lung metastasesPaul Okunieff
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA
Acta Oncol 45:808-17. 2006..Median survival time and progression-free survival both appear better than that achieved with standard care alone. Long-term progression-free survival can be seen in a subset of patients when all tumors are targeted... - Normal tissue tolerance dose metrics for radiation therapy of major organsMichael T Milano
Department of Radiation Oncology and James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Semin Radiat Oncol 17:131-40. 2007..This review summarizes the published clinical data on the risk of late toxicity as a function of quantitative dose metrics and attempts to offer suggested dose constraints for radiation treatment planning...